FDA Approves Biosimilar Ziextenzo (pegfilgrastim-bmez)

On Nov. 5, Sandoz, a Novartis division, announced U.S. Food and Drug Administration (FDA) approval of the company's biosimilar ZiextenzoTM (pegfilgrastim-bmez).

Ziextenzo is indicated to decrease the incidence of infection, as manifested by febrile neutropenia (low white blood cell count with a fever), in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Read company press release.

Posted 11/5/2019